Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 12/20 | 0.63 |
| ▸ | CA2 | P00918 | 12/20 | 0.63 |
| ▸ | CA9 | Q16790 | 10/20 | 0.63 |
| ▸ | CA5A | P35218 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | CA6 | P23280 | 5/20 | 0.50 |
| ▸ | CA4 | P22748 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA7 | P43166 | 4/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 2/20 | 0.48 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7107769 | 0.98 | CA1 (0.61) | CA1CA2CA9CA5AKDM4E | |
| SCHEMBL27271173 | 0.83 | KDM4E (0.50) | CA1CA2CA9CA5AKDM4E | |
| SCHEMBL1498169 | 0.83 | KDM4E (0.50) | CA1CA2CA9CA5AKDM4E | |
| SCHEMBL353738 | 0.83 | CA1 (0.63) | CA1CA2CA9CA5AKDM4E | |
| SCHEMBL10499129 | 0.83 | KDM4E (0.50) | CA1CA2CA9CA5AKDM4E | |
| SCHEMBL31191409 | 0.83 | CA1 (0.63) | CA1CA2CA9CA5AKDM4E | |
| SCHEMBL23849489 | 0.82 | CA2 (0.49) | CA1CA2CA9CA5AKDM4E | |
| SCHEMBL364343 | 0.81 | BCAT2 (0.56) | CA1CA2CA9CA5AKDM4E | |
| SCHEMBL8517044 | 0.81 | KDM4E (0.48) | CA1CA2CA9CA5AKDM4E | |
| SCHEMBL8517045 | 0.81 | KDM4E (0.48) | CA1CA2CA9CA5AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022351-A1 | COMPOUNDS AND METHODS FOR CHEMICALLY TAGGING MACROMOLECULE CARGO INSIDE AND OUTSIDE OF VIRUS-LIKE PARTICLES | UNIV INDIANA TRUSTEES (US) | 2026-01-22 | — | — | US | claimed |
| WO-2024206663-A1 | REACTIVE CAPSID PROTEIN ASSOCIATED MOLECULES | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2024-10-03 | — | — | WO | claimed |
| US-10759774-B2 | Inhibitors of hepatitis B virus targeting capsid assembly | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2020-09-01 | — | — | US | claimed |
| CN-109879799-B | Sulfamoyl benzamide compound containing 4-carbonyloxypiperidine and preparation method thereof | 浙江司太立制药股份有限公司 | 2020-08-11 | — | — | CN | claimed |
| US-20190092742-A1 | INHIBITORS OF HEPATITIS B VIRUS TARGETING CAPSID ASSEMBLY | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2019-03-28 | — | — | US | claimed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| US-20170240556-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | 4SC DISCOVERY GMBH (DE) | 2017-08-24 | — | — | US | claimed |
| US-9580438-B2 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders | 4SC DISCOVERY GMBH (DE) | 2017-02-28 | — | — | US | claimed |
| US-20150158878-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | 4SC DISCOVERY GMBH (DE) | 2015-06-11 | — | — | US | claimed |
| EP-2234993-B1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2012-11-07 | — | — | EP | claimed |
| US-7407977-B2 | Substituted N-acyl-2-aminothiazoles | HOFFMAN-LA ROCHE INC. (US) | 2008-08-05 | — | — | US | claimed |
| WO-2007137962-A1 | THIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-06 | — | — | WO | claimed |
| EP-1791822-A1 | SUBSTITUTED N-ACYL-2-AMINOTHIAZOLES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| US-20060030589-A1 | Substituted N-acyl-2-aminothiazoles | HOFFMANN-LA ROCHE INC. | 2006-02-09 | — | — | US | claimed |
| WO-2006013054-A1 | SUBSTITUTED N-ACYL-2-AMINOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| JP-2003504401-A | — | — | 2003-02-04 | — | — | JP | claimed |
| EP-1202724-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-05-08 | — | — | EP | claimed |
| WO-2001005393-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190092742-A1 | INHIBITORS OF HEPATITIS B VIRUS TARGETING CAPSID ASSEMBLY | HAVCR2, ZC3HAV1, HCCS | CA1 3326/4885CA2 4189/4885CA9 3855/4885 |
| US-20260022351-A1 | COMPOUNDS AND METHODS FOR CHEMICALLY TAGGING MACROMOLECULE CARGO INSIDE AND OUTSIDE OF VIRUS-LIKE PARTICLES | SPPL2A, SUMO2, UBAP2L | CA1 3446/4885CA2 3584/4885CA9 3262/4885 |
| US-20170240556-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | CNKSR1, TYK2, ERBB2 | CA1 1251/4885CA2 298/4885CA9 600/4885 |
| US-20150158878-A1 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS | CHUK, KYNU, BLK | CA1 2283/4885CA2 970/4885CA9 2138/4885 |
| US-20060030589-A1 | Substituted N-acyl-2-aminothiazoles | SLC5A2, ABAT, AGTR2 | CA1 4421/4885CA2 535/4885CA9 1874/4885 |
| US-10759774-B2 | Inhibitors of hepatitis B virus targeting capsid assembly | HAVCR2, ZC3HAV1, HCCS | CA1 3326/4885CA2 4189/4885CA9 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.